APA

Mochtar C. A., Kiemeney L. A. L. M., Laguna M. P., van Riemsdijk M. M., Barnett G. S., Debruyne F. M. J. & de la Rosette J. J. M. C. H. (20051005). Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. : Urology.

Chicago

Mochtar C A, Kiemeney L A L M, Laguna M P, van Riemsdijk M M, Barnett G S, Debruyne F M J and de la Rosette J J M C H. 20051005. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. : Urology.

Harvard

Mochtar C. A., Kiemeney L. A. L. M., Laguna M. P., van Riemsdijk M. M., Barnett G. S., Debruyne F. M. J. and de la Rosette J. J. M. C. H. (20051005). Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. : Urology.

MLA

Mochtar C A, Kiemeney L A L M, Laguna M P, van Riemsdijk M M, Barnett G S, Debruyne F M J and de la Rosette J J M C H. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. : Urology. 20051005.